RADX Stock Price, Chart, Stats & News
Radiopharm Theranostics Limited (RADX) does not currently pay a dividend.
RADX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | – |
ROE | – |
D/E | – |
Interest coverage ratio | – |
RADX valuation
P/E | – |
P/S | – |
P/B | – |
P/CF | – |
P/FCF | -0.36x |
P/OCF | – |
PEG | – |
EV multiple | – |
About
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers).
Similar securities
Based on sector and market capitalization
